Costa Pedro F, Martins Albino, Neves Nuno M, Gomes Manuela E, Reis Rui L
1 3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho , Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, Guimarães, Portugal .
Tissue Eng Part B Rev. 2014 Dec;20(6):567-77. doi: 10.1089/ten.TEB.2013.0751. Epub 2014 Jul 31.
Bone diseases and injuries are highly incapacitating and result in a high demand for tissue substitutes with specific biomechanical and structural features. Tissue engineering has already proven to be effective in regenerating bone tissue, but has not yet been able to become an economically viable solution due to the complexity of the tissue, which is very difficult to be replicated, eventually requiring the utilization of highly labor-intensive processes. Process automation is seen as the solution for mass production of cellularized bone tissue substitutes at an affordable cost by being able to reduce human intervention as well as reducing product variability. The combination of tools such as medical imaging, computer-aided fabrication, and bioreactor technologies, which are currently used in tissue engineering, shows the potential to generate automated production ecosystems, which will, in turn, enable the generation of commercially available products with widespread clinical application.
骨疾病和损伤具有高度致残性,因此对具有特定生物力学和结构特征的组织替代物有很高的需求。组织工程已被证明在骨组织再生方面是有效的,但由于组织的复杂性,它尚未成为一种经济上可行的解决方案,这种复杂性很难复制,最终需要使用高度劳动密集型的工艺。过程自动化被视为以可承受的成本大规模生产细胞化骨组织替代物的解决方案,因为它能够减少人为干预并降低产品变异性。目前在组织工程中使用的医学成像、计算机辅助制造和生物反应器技术等工具的组合,显示出产生自动化生产生态系统的潜力,这反过来又将使具有广泛临床应用的商业产品得以生产。